FDA extends review of Amicus muscle disorder therapy for second time

Amicus Therapeutics

28/10/2022 21:08

Oct 28 xx (Reuters) - The U.S. Food and Drug
Administration on Friday extended for the second time its review
of Amicus Therapeutics Inc's  FOLD.O  experimental combination
therapy to treat a rare genetic disorder that causes muscle
impairment.
 (Reporting by Khushi Mandowara and Bhanvi Satija in Bengaluru;
Editing by Sriraj Kalluvila and Devika Syamnath)
 ((Khushi.Mandowara@thomsonreuters.com))